RJFSA
ORMP icon

Raymond James Financial Services Advisors’s Oramed Pharmaceuticals ORMP Stock Holding History

Raymond James Financial Services Advisors’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-10,372
Closed -$67K – 3345
2022
Q3 		$67K Sell
10,372
-200
-2% -$1.62K ﹤0.01% 3056
2022
Q2 		$48K Buy
+10,572
New +$56.5K ﹤0.01% 3093

Other funds holding ORMP

Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
LC
Lindbrook Capital Calabasas, California $1.08B AUM 10.14% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Raymond James Financial Services Advisors's ORMP Position: Q4 2022 in Review

Raymond James Financial Services Advisors sold out of Oramed Pharmaceuticals (ORMP) in Q4 2022, closing a stake of 10,372 shares — an estimated $67K sold.

Raymond James Financial Services Advisors first reported a position in ORMP in Q2 2022 and held it in 2 quarters. The position peaked at $67K in Q3 2022. 77 funds tracked by Wall St. Rank hold ORMP as of Q4 2022.

  • Raymond James Financial Services Advisors reported no remaining Oramed Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Raymond James Financial Services Advisors sold 10,372 Oramed Pharmaceuticals shares in Q4 2022, an estimated $67K.
  • Raymond James Financial Services Advisors first reported a position in Oramed Pharmaceuticals in Q2 2022 and held it in 2 quarters.
  • Raymond James Financial Services Advisors's Oramed Pharmaceuticals position peaked at $67K in Q3 2022.
  • 77 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q4 2022.

Based on Raymond James Financial Services Advisors's 13F filing for Q4 2022, filed 8 Feb 2023.